Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSir Mortimer B. Davis - Jewish General Hospital
About this trial
The purpose :
Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Eligibility criteria
Qualifiers
Confirmed MM diagnosis
Transplant eligible patients in a first remission
Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
Availability of deidentified patient's demographic and clinical follow up data
Disqualifiers
Failure to meet inclusion criteria
Trial design
Treatments tested in this trial
- Standard of care
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov